相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Body mass index and prognosis of breast cancer An analysis by menstruation status when breast cancer diagnosis
Li Sun et al.
MEDICINE (2018)
Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features
Kristine Astvatsaturyan et al.
PLOS ONE (2018)
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Angela Santonja et al.
Oncotarget (2018)
Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution experience.
Chad Glisch et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
Chun-Yu Liu et al.
PLOS ONE (2017)
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanovic et al.
CLINICAL CANCER RESEARCH (2017)
Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers
Sergio Mitsuo Masili-Oku et al.
BREAST (2017)
Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm
Lynn Jongen et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Clinical implications of the intrinsic molecular subtypes of breast cancer
Aleix Prat et al.
BREAST (2015)
Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes
Napa Parinyanitikul et al.
CLINICAL BREAST CANCER (2015)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer
Jung Eun Choi et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women
Shuang Hao et al.
PLOS ONE (2015)
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
Helene Bonsang-Kitzis et al.
PLOS ONE (2015)
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Peter Widschwendter et al.
BREAST CANCER RESEARCH (2015)
Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype
Lee J. McGhan et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer
Aye Aye Thike et al.
MODERN PATHOLOGY (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
Brian D. Lehmann et al.
BREAST CANCER RESEARCH (2014)
Expression of androgen receptors in triple negative breast carcinomas
Ivana Mrklic et al.
ACTA HISTOCHEMICA (2013)
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B. Gerber et al.
ANNALS OF ONCOLOGY (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL CANCER RESEARCH (2013)
The Impact of Androgen Receptor Expression on Breast Cancer Survival: A Retrospective Study and Meta-Analysis
Qing Qu et al.
PLOS ONE (2013)
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers
O. Brouckaert et al.
ANNALS OF ONCOLOGY (2012)
Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer
Shaheenah Dawood et al.
CANCER BIOMARKERS (2012)
The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer
Dabei Tang et al.
MEDICAL ONCOLOGY (2012)
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
Jiehua He et al.
MEDICAL ONCOLOGY (2012)
Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers
S. Park et al.
ANNALS OF ONCOLOGY (2011)
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Rong Hu et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
Laura C. Collins et al.
MODERN PATHOLOGY (2011)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
Donata Micello et al.
VIRCHOWS ARCHIV (2010)
Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition
Laura Baglietto et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Amelia A. Peters et al.
CANCER RESEARCH (2009)
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2009)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Androgen receptor expression in estrogen receptor-negative breast cancer - Immunohistochemical, clinical, and prognostic associations
SN Agoff et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
分享论文
